ArticleJournal of gastrointestinal oncology2026
Molecular subtyping and prognostic model construction based on endosome-related genes in colorectal cancer.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Platelet-Related Signature in Colorectal Cancer: Prognosis and Therapy Guidance.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The endosome plays a crucial role in tumor cell material transport, signal regulation, and tumor immune microenvironment modeling, but the molecular characteristics, subtyping significance, and prognostic value of endosome-related genes (ERGs) in colorectal cancer (CRC) have not been systematically elucidated. This study aims to analyze the molecular heterogeneity of CRC from the perspective of ERGs and evaluate ERGs' clinical and therapeutic significance. Methods: The transcriptome and clinical data of CRC from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were integrated, identifying 63 CRC-related ERGs. Molecular typing of CRC samples was conducted based on consensus clustering analysis, and comparison of differences in survival outcomes, tumor immune microenvironment characteristics, and potential response to immunotherapy was performed among different subtypes. An ERG prognostic risk model was constructed through differential expression analysis and was validated in an independent cohort. Combining functional experiments and drug sensitivity analysis, the potential mechanisms and therapeutic value of key genes were investigated. Results: The CRC samples were divided into two significantly different subtypes of endosome-related molecules (cluster 1 and cluster 2). Compared with cluster 2, cluster 1 patients had better overall survival rates, more active immune cell infiltration (such as B cell and mast cell enrichment), and lower Tumor Immune Dysfunction and Exclusion (TIDE) scores, suggesting that they may be more likely to benefit from immune checkpoint inhibitor therapy. The prognostic model constructed based on 8-ERGs showed good predictive performance in both the training and validation sets. Further analysis revealed that the key prognostic gene Conclusions: This study systematically revealed the molecular heterogeneity of CRC from the perspective of ERGs, identified clinically significant prognostic subtypes, and key gene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.